[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570656":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":61,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":26,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Participants randomized to this arm will receive Vascepa for 6 months.",[13],"Drug: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants randomized to this arm will receive placebo for 6 months.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]","Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo twice daily",[15],[31],{"name":32,"affiliation":5,"role":33},"Kevin Boczar, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","1-613-696-7000","kboczar@ottawaheart.ca",{"name":40,"role":36,"phone":37,"phoneExt":26,"email":41},"Ashley Cowan, BScN","acowan@ottawaheart.ca",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Ottawa Heart Institute","RECRUITING","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-75.69812,45.41117,{"lat":55,"lon":54},[58,60],{"name":59,"role":36,"phone":37,"phoneExt":26,"email":38},"Kevin Boczar",{"name":40,"role":36,"phone":37,"phoneExt":26,"email":41},{"type":62,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100570656","phase-3-targeting-vascular-inflammation-in-patients-with-community-acquired-pneumonia-100570656",false,"NCT06710080","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial","TIN-CAP","Inclusion Criteria:\n\nPatients who have:\n\n1. Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)\n2. age \\> 18 years;\n3. given informed consent.\n\nExclusion Criteria:\n\nPatients who have:\n\n1. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix).\n2. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));\n3. pregnancy (all women of child bearing potential will have a negative BHCG test;\n4. breastfeeding;\n5. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.\n6. Allergies to icosapent ethyl\n7. allergies to fish or shellfish\n8. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2 (excluded from CTA portion)\n9. unable to give informed consent;\n\nExclusion for CTA portion of the protocol:\n\nPatients with dye allergy will not undergo CTA but will have PET\u002FCT","ALL","18 Years",{"count":74,"type":75},168,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:\n\nWhat is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.\n\nParticipants wil:\n\n* take Vacscepa or a placebo twice a day for 6 months\n* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests",[81,82,83],"Inflammation","Community Acquired Pneumonia (CAP)","Inflammation Plaque, Atherosclerotic",[85,86,81,87],"Community-Acquired Infection","Plaque, atherosclerotic","Eicosapentaenoic Acid","2026-05-08",{"date":90,"type":91},"2026-05-11","ACTUAL",{"date":93,"type":91},"2026-04-08",{"date":95,"type":75},"2027-06",{"name":5,"class":6},1]